Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448406 | 0.86 | TLR7 (0.56) | RAB9ATLR7ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL6452299 | 0.85 | L3MBTL1 (0.51) | RAB9ATLR7ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL6454315 | 0.82 | KAT6A (0.65) | KAT6ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL6467701 | 0.82 | SMN1; SMN2 (0.54) | RAB9AALDH1A1NPC1SMN1; SMN2GAA | |
| SCHEMBL6461094 | 0.80 | SMN1; SMN2 (0.51) | KAT6ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL15988703 | 0.78 | CTNNB1 (0.58) | KAT6ACNR2 | |
| SCHEMBL6450415 | 0.75 | ALDH1A1 (0.70) | KAT6ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL7047527 | 0.75 | P2RX7 (0.47) | TLR7GAALMNACNR2TRPV1 | |
| SCHEMBL5709026 | 0.74 | TRPV1 (0.60) | ALDH1A1GAALMNAKDM4ETRPV1 | |
| SCHEMBL9830646 | 0.74 | GAA (0.75) | KAT6ARAB9ASMN1; SMN2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | KAT6A 1911/4885RAB9A 2483/4885TLR7 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.